معرفی
Delphine Joseph is a prominent researcher in pharmacochemistry at the University of Paris-Saclay's Faculty of Pharmacy, serving as director of the Graduate School of Health & Drug Sciences and deputy director of the BioCIS laboratory (Biomolecules: Design, Isolation, Synthesis). Her leadership spans academic administration, research direction, and teaching innovation within the University Paris-Saclay ecosystem.
Her research focuses on two major areas: tobacco addiction mechanisms through nicotinic receptor studies funded by ANR, and drug allergy research particularly regarding neuromuscular blocking agents funded by Anses. Joseph employs a multidisciplinary approach integrating chemistry, biology, and bioinformatics to develop therapeutic solutions and diagnostic strategies. Her work on tobacco addiction targets molecular-level understanding of receptor movements to design targeted molecules, while her allergy research investigates molecular mechanisms of reactions to curare-based medications.
Joseph's leadership extends to directing the Graduate School of Health & Drug Sciences, which unites academic and research teams from multiple universities and research organizations (CNRS, Inserm, CEA, INRAE) around drug development and therapeutic innovation. She champions interdisciplinary collaboration through initiatives like mixed cohort events and research days designed to foster innovative projects.
- PEPS (Passion for Teaching and Pedagogy in Higher Education) Prize recipient
- ANR-funded research on nicotinic receptors for tobacco addiction treatment
- Anses-funded project on drug allergy mechanisms to neuromuscular blocking agents
- Leadership in reforming organic chemistry teaching curricula
Her research demonstrates consistent thematic focus on molecular design for therapeutic applications, with increasing emphasis on computational approaches and interdisciplinary collaboration. Recent publications reflect growing integration of bioinformatics with experimental validation, particularly in fragment-based drug design and molecular dynamics studies targeting specific receptor interfaces. Joseph maintains strong industry connections through past collaborations with Novartis and Menarini, and current partnerships with UCB Pharma.
